Analysts Set Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Target Price at $45.43

Shares of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) have earned an average recommendation of “Moderate Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $45.4286.

A number of brokerages recently commented on CRBP. Oppenheimer lowered their price objective on Corbus Pharmaceuticals from $56.00 to $53.00 and set an “outperform” rating for the company in a research report on Wednesday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a research report on Wednesday, October 8th. B. Riley upgraded shares of Corbus Pharmaceuticals to a “strong-buy” rating and set a $28.00 price target for the company in a research report on Wednesday, July 30th. Lifesci Capital upgraded shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research report on Saturday, July 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Corbus Pharmaceuticals in a research report on Wednesday, September 17th.

Corbus Pharmaceuticals Stock Performance

Corbus Pharmaceuticals stock opened at $19.32 on Wednesday. The firm has a market cap of $236.86 million, a P/E ratio of -4.06 and a beta of 2.84. The business’s fifty day moving average is $11.62 and its two-hundred day moving average is $9.01. Corbus Pharmaceuticals has a 52 week low of $4.64 and a 52 week high of $20.77.

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.44) EPS for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.11. On average, equities research analysts predict that Corbus Pharmaceuticals will post -4.23 earnings per share for the current year.

Institutional Investors Weigh In On Corbus Pharmaceuticals

Several institutional investors have recently modified their holdings of the business. Exome Asset Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the 1st quarter worth approximately $1,538,000. Armistice Capital LLC grew its position in shares of Corbus Pharmaceuticals by 5.9% during the 1st quarter. Armistice Capital LLC now owns 250,000 shares of the biopharmaceutical company’s stock worth $1,328,000 after buying an additional 14,000 shares during the period. Comerica Bank boosted its stake in Corbus Pharmaceuticals by 20,000,000.0% during the 1st quarter. Comerica Bank now owns 200,001 shares of the biopharmaceutical company’s stock worth $1,062,000 after acquiring an additional 200,000 shares during the last quarter. Acadian Asset Management LLC acquired a new position in Corbus Pharmaceuticals during the first quarter valued at approximately $1,007,000. Finally, Atle Fund Management AB grew its holdings in Corbus Pharmaceuticals by 78.6% during the second quarter. Atle Fund Management AB now owns 175,582 shares of the biopharmaceutical company’s stock valued at $1,212,000 after purchasing an additional 77,278 shares during the period. Institutional investors and hedge funds own 64.64% of the company’s stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.